Milestone Pharmaceuticals announced a poster presentation at the American College of Cardiology annual meeting (ACC25) from March 29th-31st, 2025, in Chicago. The presentation will focus on data from the NODE-303 trial demonstrating etripamil’s potential to consistently convert multiple episodes of Paroxysmal Supraventricular Tachycardia (PSVT) and restore normal sinus rhythm. Dr. James Ip, Associate Professor at Weill Cornell Medicine, will present the findings on March 30th.
This research holds substantial implications for managing PSVT. The ability of a patient to self-administer a nasal spray like etripamil to treat successive episodes offers significant advantages over current treatment options, which often involve a visit to a healthcare facility or more invasive interventions. Positive data reinforces the drug’s potential to improve patient quality of life by providing a convenient and effective way to control their condition independently and prevent recurrent, disruptive PSVT episodes.
The NODE-303 trial data suggests that etripamil’s success in converting earlier PSVT episodes is a strong predictor of success in subsequent episodes. This predictive capability is crucial for patients and clinicians, providing confidence in the medication’s reliability during a PSVT event. This information will be highly relevant to cardiologists and potentially influence treatment guidelines for PSVT if the drug receives approval.
The presentation of this data at a prominent cardiology conference signifies growing interest in etripamil as a potential treatment option for PSVT. Positive findings could bolster Milestone Pharmaceuticals’ position in the cardiovascular market and potentially pave the way for regulatory approval and commercialization of etripamil, representing a significant advancement in patient care for those experiencing PSVT.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
